GPRC5D Antibody (E-2): sc-515733
- GPRC5D Antibody (E-2) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 7-24 within an extracellular domain of GPRC5D of mouse origin
- recommended for detection of GPRC5D of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for GPRC5D Antibody (E-2) for WB applications. These reagents are now offered in bundles with GPRC5D Antibody (E-2) (see ordering information below).
QUICK LINKS
SEE ALSO...
GPRC5D Antibody (E-2) is a mouse monoclonal IgG1 antibody that detects GPRC5D in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GPRC5D, a 344 amino acid protein encoded by the mouse Gprc5d gene, is an orphan receptor belonging to the G-protein coupled receptor family C group 5 and is part of the RAIG family. GPRC5D (E-2) antibody recognizes a protein characterized by seven transmembrane domains, which are crucial for transducing extracellular signals via heterotrimeric G proteins. GPRC5D′s significance stems from potential interactions with retinoid and G-protein signaling pathways, suggesting a key role in cellular communication and response mechanisms. Anti-GPRC5D antibody (E-2) targets a protein predominantly found in hard keratinized structures, highlighting relevance in skin and hair biology, where GPRC5D may influence tissue maturation and maintenance. GPRC5D (E-2) monoclonal antibody serves as an essential tool for researchers investigating receptor dynamics and physiological implications.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GPRC5D Antibody (E-2) References:
- GPRC5D-Targeted CAR T Cells for Myeloma. | Quintás-Cardama, A. 2022. N Engl J Med. 387: 2295-2296. PMID: 36516097
- GPRC5D-targeted bispecific bolsters T-cell-engager pipeline. | Mullard, A. 2023. Nat Rev Drug Discov. 22: 90. PMID: 36627442
- Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. | Derrien, J., et al. 2023. Nat Cancer. 4: 1536-1543. PMID: 37653140
- The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer. | Yan, P., et al. 2024. Nat Commun. 15: 5255. PMID: 38898050
- Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. | Zhou, D., et al. 2024. Lancet Haematol. 11: e751-e760. PMID: 39059405
- Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma. | Jeong, J., et al. 2024. J Mol Biol. 436: 168748. PMID: 39181182
- Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma. | Shaver, J., et al. 2025. Ann Pharmacother. 59: 350-363. PMID: 39192558
- Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D-CAR T cells. | Hu, X., et al. 2024. Br J Haematol. 205: 2049-2052. PMID: 39228074
- Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. | Merz, M., et al. 2024. Blood Cancer J. 14: 214. PMID: 39632797
- Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. | Braun, T., et al. 2025. Nat Med.. PMID: 39984633
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPRC5D Antibody (E-2) | sc-515733 | 200 µg/ml | $322.00 | |||
GPRC5D Antibody (E-2): m-IgG Fc BP-HRP Bundle | sc-538821 | 200 µg Ab; 10 µg BP | $361.00 | |||
GPRC5D Antibody (E-2): m-IgGκ BP-HRP Bundle | sc-536496 | 200 µg Ab; 40 µg BP | $361.00 | |||
GPRC5D Antibody (E-2): m-IgG1 BP-HRP Bundle | sc-545896 | 200 µg Ab; 20 µg BP | $361.00 |